ESC Congress 2019 - Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
With Roxana Mehran, The Mount Sinai Hospital - USA, Jan Steffel, University Hospital Zurich - Switzerland a Diana Gorog, University of Hertfordshire - UK Link to paper:
